Literature DB >> 18778855

Both Met(109) and Met(112) are utilized for Cu(II) coordination by the amyloidogenic fragment of the human prion protein at physiological pH.

Jason Shearer1, Pamela Soh, Stefanie Lentz.   

Abstract

The prion protein is a ubiquitous neuronal membrane protein. Misfolding of the prion protein has been implicated in transmissible spongiform encephalopathies (prion diseases). It has been demonstrated that the human prion protein (PrP) is capable of coordinating at least five Cu(II) ions under physiological conditions; four copper binding sites can be found in the octarepeat domain between residues 61 and 91, while another copper binding site can be found in the unstructured "amyloidogenic" domain between residues 91 and 126 PrP(91-126). Herein we expand upon a previous study [J. Shearer, P. Soh, Inorg. Chem. 46 (2007) 710-719] where we demonstrated that the physiologically relevant high affinity Cu(II) coordination site within PrP(91-126) is found between residues 106 and 114. It was shown that Cu(II) is contained within a square planar (N/O)3S coordination environment with one His imidazole ligand (H(111)) and one Met thioether ligand (either M(109) or M(112)). The identity of the Met thioether ligand was not identified in that study. In this study we perform a detailed investigation of the Cu(II) coordination environment within the PrP fragment containing residues 106-114 (PrP(106-114)) involving optical, X-ray absorption, EPR, and fluorescence spectroscopies in conjunction with electronic structure calculations. By using derivatives of PrP(106-114) with systematic Met-->Ile "mutations" we show that the CuII coordination environment within PrP(106-114) is actually comprised of a mixture of two major species; one Cu(II)(N/O)3S center with the M(109) thioether coordinated to CuII and another CuII(N/O)3S center with the M(112) thioether coordinated to CuII. Furthermore, deletion of one or more Met residues from the primary sequence of PrP(106-114) both reduces the CuII affinity of the peptide by two to seven fold, and renders the resulting CuII metallopeptides redox inactive. The biological implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778855      PMCID: PMC2657601          DOI: 10.1016/j.jinorgbio.2008.07.016

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  43 in total

1.  Mononuclear N3S(thioether)-ligated copper(II) methoxide complexes: synthesis, characterization, and hydrolytic reactivity.

Authors:  Kyle J Tubbs; Amy L Fuller; Brian Bennett; Atta M Arif; Lisa M Berreau
Journal:  Inorg Chem       Date:  2003-08-11       Impact factor: 5.165

2.  Transmissible spongiform encephalopathies: prion proof in progress.

Authors:  Herman K Edskes; Reed B Wickner
Journal:  Nature       Date:  2004-08-26       Impact factor: 49.962

Review 3.  Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis).

Authors:  Elena Gaggelli; Henryk Kozlowski; Daniela Valensin; Gianni Valensin
Journal:  Chem Rev       Date:  2006-06       Impact factor: 60.622

4.  Prion protein selectively binds copper(II) ions.

Authors:  J Stöckel; J Safar; A C Wallace; F E Cohen; S B Prusiner
Journal:  Biochemistry       Date:  1998-05-19       Impact factor: 3.162

5.  Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans.

Authors:  M R Scott; R Will; J Ironside; H O Nguyen; P Tremblay; S J DeArmond; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  Copper(II) binding modes in the prion octapeptide PHGGGWGQ: a spectroscopic and voltammetric study.

Authors:  R P Bonomo; G Imperllizzeri; G Pappalardo; E Rizzarelli; G Tabbì
Journal:  Chemistry       Date:  2000-11-17       Impact factor: 5.236

7.  Preferential Cu2+ coordination by His96 and His111 induces beta-sheet formation in the unstructured amyloidogenic region of the prion protein.

Authors:  Christopher E Jones; Salama R Abdelraheim; David R Brown; John H Viles
Journal:  J Biol Chem       Date:  2004-05-15       Impact factor: 5.157

8.  Copper stimulates endocytosis of the prion protein.

Authors:  P C Pauly; D A Harris
Journal:  J Biol Chem       Date:  1998-12-11       Impact factor: 5.157

Review 9.  Barriers to drug discovery and development for Alzheimer disease.

Authors:  Howard M Fillit; Alan W O'Connell; William M Brown; Larry D Altstiel; Ravi Anand; Katherine Collins; Steven H Ferris; Zaven S Khachaturian; June Kinoshita; Linda Van Eldik; C Forbes Dewey
Journal:  Alzheimer Dis Assoc Disord       Date:  2002       Impact factor: 2.703

10.  Fragment length influences affinity for Cu2+ and Ni2+ binding to His96 or His111 of the prion protein and spectroscopic evidence for a multiple histidine binding only at low pH.

Authors:  Mark Klewpatinond; John H Viles
Journal:  Biochem J       Date:  2007-06-15       Impact factor: 3.857

View more
  4 in total

Review 1.  Redox control of prion and disease pathogenesis.

Authors:  Neena Singh; Ajay Singh; Dola Das; Maradumane L Mohan
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

2.  Identification of the minimal copper(II)-binding alpha-synuclein sequence.

Authors:  Mark S Jackson; Jennifer C Lee
Journal:  Inorg Chem       Date:  2009-10-05       Impact factor: 5.165

3.  Copper-induced structural propensities of the amyloidogenic region of human prion protein.

Authors:  Caterina Migliorini; Adalgisa Sinicropi; Henryk Kozlowski; Marek Luczkowski; Daniela Valensin
Journal:  J Biol Inorg Chem       Date:  2014-04-16       Impact factor: 3.358

4.  Spectroscopic and Theoretical Study of Cu(I) Binding to His111 in the Human Prion Protein Fragment 106-115.

Authors:  Trinidad Arcos-López; Munzarin Qayyum; Lina Rivillas-Acevedo; Marco C Miotto; Rafael Grande-Aztatzi; Claudio O Fernández; Britt Hedman; Keith O Hodgson; Alberto Vela; Edward I Solomon; Liliana Quintanar
Journal:  Inorg Chem       Date:  2016-03-01       Impact factor: 5.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.